STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S.

FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Rheumatic disorders affect 25% of people, with autoimmune diseases like rheumatoid arthritis and lupus impacting women of ...

SUGAR LAND, Texas--(BUSINESS WIRE)--FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric clinical trial, to evaluate if ...

FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric ... arthritis, chronic musculoskeletal pain, severe osteoarthritis ...

South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

moderate to severely plaque psoriasis for adult patients and pediatric patients six years or older, who are candidates for ...

while there have been six approvals for juvenile psoriatic arthritis. Systemic JIA only has two approvals, while enthesitis related arthritis — the pediatric equivalent of adult ...